Prognostic value of early changes in artificial intelligence-based computed tomography-measured body composition in pediatric osteosarcoma receiving neoadjuvant chemotherapy

Table 1 Demographic and clinical characteristics, n (%)/median (interquartile range)

Variable	Overall (n = 133)
Age, years	15 (4)
Gender
Male	72 (54.1)
Female	61 (45.9)
Location
Axial	21 (15.8)
Pelvis	-14 (10.5)
Spine	-7 (5.3)
Limb	112 (84.2)
Distal femur	-52 (39.1)
Proximal tibia	-38 (28.6)
Proximal humerus	-14 (10.5)
Others	-8 (6.0)
Maxium tumor length, cm	10.0 (7.0)
BMI, kg/m2	18.36 (4.59)
Pre-chemotherapy indexes
VATI, cm2/m2	10.13 (11.80)
SATI, cm2/m2	16.57 (24.05)
SMI, cm2/m2	34.20 (12.75)
SMD, HU	45.66 (7.72)
Albumin, g/L	43.3 (5.4)
Platelet count, 109/L	238 (141)
Neutrophil count, 109/L	4.07 (3.20)
Lymphocyte count, 109/L	1.57 (0.91)
ALP, g/L	155 (153)
SII	642.6 (689.6)
PNI	51.15 (5.48)
Post-chemotherapy indexes
VATI, cm2/m2	10.41 (14.15)
SATI, cm2/m2	17.03 (25.44)
SMI, cm2/m2	34.05 (11.72)
SMD, HU	44.75 (8.06)
Albumin, g/L	39.9 (7.7)
Platelet count, 109/L	227 (145)
Neutrophil count, 109/L	5.96 (5.13)
Lymphocyte count, 109/L	1.33 (0.90)
ALP, g/L	125 (123)
SII	1240.1 (1341.0)
PNI	46.03 (10.55)
ΔVATI, cm2/m2/30 days	1.29 (5.57)
ΔSATI, cm2/m2/30 days	1.27 (7.94)
ΔSMI, cm2/m2/30 days	0.68 (3.85)
ΔSMD, HU/30 days	1.01 (3.36)
ΔSII, score/30 days	754.1 (1416.4)
ΔPNI, score/30 days	6.38 (9.16)
Histopathological response to neoadjuvant chemotherapy
Non-responder	20 (15.0)
Responder	113 (85.0)

Δ: Body compartment area change per 30 days. BMI: Body mass index; VATI: Visceral adipose tissue index; SATI: Subcutaneous adipose tissue index; SMI: Skeletal muscle index; SMD: Skeletal muscle density; HU: Hounsfield unit; ALP: Alkaline phosphatase; SII: Systemic immune-inflammation index; PNI: Prognostic nutritional index.